Comprehensive Stock Comparison
Compare Soleno Therapeutics, Inc. (SLNO) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | SLNO | 11.0% net margin vs AGIO's -9.0% |
| Stability / Safety | SLNO | Beta 0.68 vs AGIO's 0.91, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | AGIO | -14.9% vs SLNO's -20.0% |
| Efficiency (ROA) | SLNO | 3.7% ROA vs AGIO's -29.0%, ROIC 15.6% vs -26.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Soleno Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for rare diseases. It currently generates no revenue from commercial sales — its financial runway comes from equity financing and potential milestone payments — with its lead candidate in Phase III trials for Prader-Willi syndrome. The company's competitive advantage lies in its focused expertise on rare disease therapeutics and its lead candidate's potential to address a significant unmet medical need in Prader-Willi syndrome.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
SLNO leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). AGIO leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Financial Metrics (TTM)
SLNO is the larger business by revenue, generating $190M annually — 4.3x AGIO's $45M. SLNO is the more profitable business, keeping 11.0% of every revenue dollar as net income compared to AGIO's -9.0%.
| Metric | SLNOSoleno Therapeuti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $190M | $45M |
| EBITDAEarnings before interest/tax | $61M | -$470M |
| Net IncomeAfter-tax profit | $21M | -$401M |
| Free Cash FlowCash after capex | $47M | -$414M |
| Gross MarginGross profit ÷ Revenue | +50.9% | +84.4% |
| Operating MarginEBIT ÷ Revenue | +32.4% | -10.6% |
| Net MarginNet income ÷ Revenue | +11.0% | -9.0% |
| FCF MarginFCF ÷ Revenue | +24.6% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +163.0% | -111.0% |
Valuation Metrics
| Metric | SLNOSoleno Therapeuti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $145,692 | $2.25T |
| Enterprise ValueMkt cap + debt − cash | -$67M | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | 100.18x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.28x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | -1.11x | — |
| Price / SalesMarket cap ÷ Revenue | 0.00x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 4.72x | 1.47x |
| Price / FCFMarket cap ÷ FCF | 0.00x | — |
Profitability & Efficiency
SLNO delivers a 4.6% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-31 for AGIO. SLNO carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AGIO's 0.03x. On the Piotroski fundamental quality scale (0–9), SLNO scores 6/9 vs AGIO's 3/9, reflecting solid financial health.
| Metric | SLNOSoleno Therapeuti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | +4.6% | -31.2% |
| ROA (TTM)Return on assets | +3.7% | -29.0% |
| ROICReturn on invested capital | +15.6% | -26.6% |
| ROCEReturn on capital employed | +15.1% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 3 |
| Debt / EquityFinancial leverage | 0.01x | 0.03x |
| Net DebtTotal debt minus cash | -$67M | -$49M |
| Cash & Equiv.Liquid assets | $70M | $89M |
| Total DebtShort + long-term debt | $3M | $40M |
| Interest CoverageEBIT ÷ Interest expense | -6.60x | — |
Total Returns (with DRIP)
A $10,000 investment in AGIO five years ago would be worth $6,363 today (with dividends reinvested), compared to $1,966 for SLNO. Over the past 12 months, AGIO leads with a -14.9% total return vs SLNO's -20.0%. The 3-year compound annual growth rate (CAGR) favors SLNO at 56.7% vs AGIO's 6.1% — a key indicator of consistent wealth creation.
| Metric | SLNOSoleno Therapeuti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -17.2% | +11.2% |
| 1-Year ReturnPast 12 months | -20.0% | -14.9% |
| 3-Year ReturnCumulative with dividends | +284.9% | +19.4% |
| 5-Year ReturnCumulative with dividends | -80.3% | -36.4% |
| 10-Year ReturnCumulative with dividends | -90.9% | -21.2% |
| CAGR (3Y)Annualised 3-year return | +56.7% | +6.1% |
Risk & Volatility
SLNO is the less volatile stock with a 0.68 beta — it tends to amplify market swings less than AGIO's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGIO currently trades 65.7% from its 52-week high vs SLNO's 43.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SLNOSoleno Therapeuti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 0.91x |
| 52-Week HighHighest price in past year | $90.32 | $46.00 |
| 52-Week LowLowest price in past year | $32.84 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +43.3% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 948K |
Analyst Outlook
Wall Street rates SLNO as "Buy" and AGIO as "Buy". Consensus price targets imply 169.3% upside for SLNO (target: $105) vs 37.3% for AGIO (target: $42).
| Metric | SLNOSoleno Therapeuti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $105.20 | $41.50 |
| # AnalystsCovering analysts | 11 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | 100 | 20.37 | -79.6% |
| Agios Pharmaceutica… (AGIO) | 100 | 57.07 | -42.9% |
Agios Pharmaceutica… (AGIO) returned -36% over 5 years vs Soleno Therapeutics… (SLNO)'s -80%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | $1M | $190M | +13024.2% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Soleno Therapeutics, Inc.'s revenue grew from $1M (2016) to $190M (2025) — a 71.9% CAGR. Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2014 | 2025 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | -41.0% | 11.0% | +126.7% |
| Agios Pharmaceutica… (AGIO) | -81.9% | -7.6% | +90.7% |
Agios Pharmaceuticals, Inc.'s net margin went from -82% (2014) to -8% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Soleno Therapeutics… (SLNO) | -58.35 | 0.39 | +100.7% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Soleno Therapeutics, Inc.'s EPS grew from $-58.35 (2016) to $0.39 (2025). Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 5Free Cash Flow — 5 Years
Soleno Therapeutics, Inc. generated $47M FCF in 2025 (+268% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
SLNO vs AGIO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SLNO or AGIO a better buy right now?
Soleno Therapeutics, Inc. (SLNO) offers the better valuation at 100.2x trailing P/E (9.3x forward), making it the more compelling value choice. Analysts rate Soleno Therapeutics, Inc. (SLNO) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SLNO or AGIO?
Over the past 5 years, Agios Pharmaceuticals, Inc. (AGIO) delivered a total return of -36.4%, compared to -80.3% for Soleno Therapeutics, Inc. (SLNO). A $10,000 investment in AGIO five years ago would be worth approximately $6K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AGIO returned -21.2% versus SLNO's -90.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SLNO or AGIO?
By beta (market sensitivity over 5 years), Soleno Therapeutics, Inc. (SLNO) is the lower-risk stock at 0.68β versus Agios Pharmaceuticals, Inc.'s 0.91β — meaning AGIO is approximately 33% more volatile than SLNO relative to the S&P 500. On balance sheet safety, Soleno Therapeutics, Inc. (SLNO) carries a lower debt/equity ratio of 1% versus 3% for Agios Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — SLNO or AGIO?
Soleno Therapeutics, Inc. (SLNO) is the more profitable company, earning 11.0% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 11.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLNO leads at 32.4% versus -873.9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is SLNO or AGIO more undervalued right now?
Analyst consensus price targets imply the most upside for SLNO: 169.3% to $105.20.
06Which pays a better dividend — SLNO or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SLNO or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Soleno Therapeutics, Inc. (SLNO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.68)). Both have compounded well over 10 years (SLNO: -90.9%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SLNO and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.